| Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015 | 8482 | 2015 |
| Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3863 | 2017 |
| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3568 | 2019 |
| Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ... The Lancet Oncology 19 (11), 1480-1492, 2018 | 1481 | 2018 |
| Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 40 (2), 127-137, 2022 | 900 | 2022 |
| The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells F Grignani, PF Ferrucci, U Testa, G Talamo, M Fagioli, M Alcalay, ... Cell 74 (3), 423-431, 1993 | 744 | 1993 |
| Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab PF Ferrucci, PA Ascierto, J Pigozzo, M Del Vecchio, M Maio, ... Annals of Oncology 27 (4), 732-738, 2016 | 424 | 2016 |
| Angiogenesis in myelodysplastic syndromes G Pruneri, F Bertolini, D Soligo, N Carboni, A Cortelezzi, PF Ferrucci, ... British journal of cancer 81 (8), 1398-1401, 1999 | 375 | 1999 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The Lancet Oncology 22 (5), 643-654, 2021 | 358 | 2021 |
| Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio, V Atkinson, H Schmidt, ... Nature medicine 25 (6), 941-946, 2019 | 317 | 2019 |
| Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma M Sznol, PF Ferrucci, D Hogg, MB Atkins, P Wolter, M Guidoboni, ... Journal of Clinical Oncology 35 (34), 3815-3822, 2017 | 314 | 2017 |
| Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial AM Di Giacomo, PA Ascierto, L Pilla, M Santinami, PF Ferrucci, ... The lancet oncology 13 (9), 879-886, 2012 | 303 | 2012 |
| Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? PF Ferrucci, E Zucca British journal of haematology 136 (4), 521-538, 2007 | 254 | 2007 |
| Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma PF Ferrucci, L Pala, F Conforti, E Cocorocchio Cancers 13 (6), 1383, 2021 | 248 | 2021 |
| Caspases mediate retinoic acid–induced degradation of the acute promyelocytic leukemia PML/RARα fusion protein C Nervi, FF Ferrara, M Fanelli, MR Rippo, B Tomassini, PF Ferrucci, ... Blood, The Journal of the American Society of Hematology 92 (7), 2244-2251, 1998 | 248 | 1998 |
| Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients PF Ferrucci, S Gandini, A Battaglia, S Alfieri, AM Di Giacomo, ... British journal of cancer 112 (12), 1904-1910, 2015 | 243 | 2015 |
| Angiogenic growth factors and endostatin in non‐Hodgkin's lymphoma F Bertolini, M Paolucci, F Peccatori, S Cinieri, A Agazzi, PF Ferrucci, ... British journal of haematology 106 (2), 504-509, 1999 | 221 | 1999 |
| Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis F Conforti, L Pala, V Bagnardi, G Viale, T De Pas, E Pagan, ... JNCI: Journal of the National Cancer Institute 111 (8), 772-781, 2019 | 197 | 2019 |
| Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma M Del Vecchio, L Di Guardo, PA Ascierto, AM Grimaldi, VC Sileni, ... European Journal of Cancer 50 (1), 121-127, 2014 | 169 | 2014 |
| KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma PF Ferrucci, AM Di Giacomo, M Del Vecchio, V Atkinson, H Schmidt, ... Journal for immunotherapy of cancer 8 (2), 2020 | 163 | 2020 |
